Eurofins Transplant Genomics

This #WorldKidneyDay, we’re spotlighting one of our team members at Eurofins Transplant Genomics, Jevon Boudreaux, whose selfless act sparked one of the largest kidney donation chains in Washington. Join us in thanking Jevon by dropping a "thank you" in the comments! ?? To learn more about improving long-term transplant outcomes, visit transplantgenomics.com.

A message directly from our world-class Customer Support Team! #WorldKidneyDay

Every kidney transplant is a second chance—a chance for more moments, more milestones, and more time. At Eurofins Transplant Genomics, we’re committed to advancing long-term transplant outcomes through innovative testing that helps detect early signs of graft injury and guides personalized care. Join us in recognizing #WorldKidneyDay and the progress being made for transplant patients everywhere. #TransplantCare #KidneyHealth

Peripheral blood gene expression profiles (GEPs) and donor-derived cell-free DNA (dd-cfDNA) are proving valuable in detecting subclinical and clinical allograft rejection. This paper highlights their potential in diagnosing persistent rejection and improving post-transplant care. Read the full study to learn more: https://ow.ly/99Om50V5z1s #KidneyTransplant #Innovation

How do you manage discordant biomarker results in kidney transplant care? In our upcoming webinar, Dr. Michael Marvin will outline a practical workflow for interpreting discordant results between TruGraf kidney and dd-cfDNA tests. This is essential for clinicians looking to stay ahead of the curve in transplant monitoring. Register now to save your spot: https://ow.ly/pWR950VaspO #Webinar #TransplantCare #KidneyHealth

Are current diagnostic tools enough for multiorgan transplant recipients? ?? “Currently, both GEP and dd-cfDNA are clinically available for kidney transplant patients. Both GEP and dd-cfDNA have been shown to be reliable “rule-out” tests for rejection in KTRs. However, the validity and utility of these tests in monitoring for renal allograft rejections in the setting of MOTs [multiorgan transplants] has yet to be investigated. The aim of this study is to evaluate the utility of GEP and dd-cfDNA as noninvasive biomarkers for renal allograft rejection in MOT recipients.” Read more: https://ow.ly/kJOk50V8pxI ?? Stephanie Clifford, James Fleming

At Eurofins Transplant Genomics, we’re dedicated to advancing transplant care—and we can’t wait to discuss the latest innovations at #RPA2025. If you’re attending, let’s connect and explore how we can improve patient outcomes together! ?? https://ow.ly/9tNP50V5yxL Ascend Clinical #TransplantCare #Nephrology

World Kidney Day is this week! Kick it off by reading and sharing the right resources. ?? The American Society of Transplantation offers tools, guides, and expert insights to support kidney transplant patients, providers, and professionals every step of the way. Learn more here: https://ow.ly/JizC50V5yaW #TransplantCare #AST #KidneyHealth

42 years after his life-saving kidney transplant, Jim continues to inspire through his advocacy and competition. At the 2024 Transplant Games, he shared his incredible journey—from receiving a kidney from his brother to witnessing decades of medical progress. ?? Watch now: https://ow.ly/YBpZ50V5xr7 We’re already looking ahead to the 2026 Transplant Games in Denver—can’t wait to see you there! Learn more: https://lnkd.in/gJp8Yq6a

Eurofins Transplant Genomics is heading to Boston for #SCM25 with our sister company, Ascend Clinical! As the premier event for the kidney health community, #SCM25 is where innovation and expertise come together. Stay tuned for more details! Learn more here: https://lnkd.in/epuiCSa #KidneyHealth National Kidney Foundation